

Thesis
Submitted for the Degree of
Master of Applied Science
of the
University of Canberra

Salivary IgA Responses During the First Two Years of Life: A
Study of Aboriginal and Non-Aboriginal Children

By
Su Mon Kyaw-Myint

Thesis Type 1

August 2003

Copyright

This thesis may be freely copied and distributed for private use and study, however, no part of this thesis or the information contained therein may be included in or referred to in a publication without prior written permission of the author. Any references must be fully acknowledged.

Signature of author 

Date 12.12.03

Acknowledgements

I would like to acknowledge the support of many people in making this thesis possible.

I am deeply indebted to my supervisors Prof. Allan Cripps, Dr Ruth Foxwell and Prof. Jennelle Kyd for their guidance and support throughout the entire project. Thank you for your enthusiasm, patience, and invaluable feedback. A special thanks to Ruth for being a great friend and for spending so much time and effort in teaching me how to write.

I also wish to thank Dr Deborah Lehmann of the Telethon Institute for Child Health Research for providing me with samples for analysis, questionnaire data, teaching me how to use SPSS and guiding me through the statistical analysis, answering my numerous questions, and her helpful comments.

I would like to thank the staff and the students at the Canberra centre for mucosal immunology whose friendship and support made it a special place of learning. I am especially grateful to Jodie Clarke for her help throughout my project and for setting up the ELISA.

I would also like to thank my parents for teaching me to value knowledge, letting me pursue my dreams, and their unconditional love and support. Eddie and Kyaw for encouraging me and believing in me and solving my computer problems. Finally, a special thanks goes to Myo for all the countless ways she has supported and taken care of me and without whom I could not have completed this thesis.

A scholarship from the University of Canberra provided tuition fees for the duration of this research program.

Abstract

Nontypeable *Haemophilus influenzae* (NTHi), *Streptococcus pneumoniae* and *Moraxella catarrhalis* are common bacterial agents of otitis media which is a major cause of morbidity in young children. Mucosal immune responses are an integral part of the immune defense against middle ear infection and it is known that certain populations, including Australian Aboriginal children, are highly susceptible to disease.

The current study focussed on the development of the mucosal immunity to the three bacterial pathogens in Aboriginal and non-Aboriginal children from birth to two years of age, living in the Kalgoorlie-Boulder region of Western Australia. Salivary and breast milk IgA levels were measured by the enzyme linked immunosorbent assay. The measured IgA levels, combined with socio-economic, demographic and bacteriological data were analyzed statistically to determine the influential factors on the mucosal IgA response in these children over time.

This study found that each antigen-specific IgA examined followed a distinct ontogeny pattern and IgA responses differed significantly according to age, indigenous status and feeding type. Indoors smoke exposure, maternal smoking, and sibling day care attendance had some impact on salivary IgA levels in the children. However, household crowding and the presence of older siblings had the most significant impact on salivary IgA levels for children of different age groups. These two factors were correlated to increased nasopharyngeal colonization by *H. influenzae*, *S. pneumoniae* and *M. catarrhalis* and colonization status was also found to influence salivary IgA levels in the children. No correlation between maternal breast milk IgA levels and child salivary IgA levels was observed.

The results suggest that the degree of exposure to environmental factors rather than immunological deficit is responsible for the observed differences in salivary IgA responses between Aboriginal and non-Aboriginal children and modifying these factors could lead to a reduction in the burden of otitis media experienced by the children. Further studies correlating specific salivary IgA levels to diseases such as otitis media will reveal the role of specific salivary IgA responses in the prevention of infection by respiratory pathogens.

Table of Contents

Chapter 1. General Introduction

1.1 Introduction	2
1.2 Mucosal immunity	3
1.2.1 Common mucosal immune system and lymphocyte traffic	4
1.2.2 Secretory IgA	5
1.2.3 Mucosal immunostimulation	7
1.3 Ontogeny of Mucosal Immunity	8
1.3.1 Fetal development	8
1.3.2 Postnatal development	9
1.4 Protective effect of Breast Feeding	13
1.5 Immune Factors in Breast Milk	15
1.6 Nasopharyngeal Colonization	18
1.7 Predominant Bacterial OM Pathogens	20
1.7.1 <i>Streptococcus pneumoniae</i>	20
1.7.2 Nontypeable <i>Haemophilus influenzae</i>	23
1.7.3 <i>Moraxella catarrhalis</i>	24
1.8 Specific Immune Response to Common Otitis Media Pathogens	26
1.9 Immune Response in Otitis Prone Children	32
1.10 Epidemiology of Otitis Media	34
1.11 Otitis Media in Aboriginal Populations	39
1.12 Long Term Effects of Otitis Media	41
1.13 Aims of the study	44

Chapter 2. Materials and Methods

2.1 Study design	46
2.1.1 Study population and recruitment	46
2.1.2 Collection of demographic, socio-economic data	46
2.1.3 Assessment of otitis media and hearing loss	47
2.1.4 Collection and storage conditions for immunological samples	47
2.1.5 Bacterial culture and carriage density	47
2.1.6 Study limitations	48
2.2 Purification of recombinant OMPE protein from <i>M. catarrhalis</i>	48
2.3 Purification of recombinant OMP26 protein from nontypeable <i>H. influenzae</i>	50
2.4 Purification of P6 from Nontypeable <i>H. influenzae</i>	51
2.5 Extraction of proteins from <i>M. catarrhalis</i>	52
2.6 Extraction of proteins from <i>S. pneumoniae</i>	53
2.7 Purification of recombinant pneumolysin toxoid (Pd-B)	54
2.8 SDS removal from purified proteins	54
2.9 Protein assay	54
2.10 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)	55
2.11 ELISA protocols	56
2.11.1 Preparation of saliva and breast milk samples	56
2.11.2 Assay development	56
2.11.3 Assay conditions	56
2.11.4 Quality controls	58
2.12 Statistical analysis	61

Chapter 3. Salivary IgA Development and Breast-Feeding

3.1 Introduction	66
3.2 Results	68
3.2.1 Salivary IgA development	69
3.2.2 Ontogeny pattern in positive responders	74
3.2.3 Influence of indigenous status on salivary IgA development	80
3.2.4 Influence of gender and indigenous status on salivary IgA development	87
3.2.5 Influence of breast-feeding on salivary IgA development	88
Independent of age	89
Subdivided by age	92
3.2.6 Influence of breast-feeding and Aboriginality on salivary IgA development	92
Aboriginal children	93
Non-Aboriginal children	94
3.3 Discussion	94

Chapter 4. Nasopharyngeal colonization with *H. influenzae*, *S. pneumoniae*, *M. catarrhalis* and the salivary IgA response

4.1 Introduction	102
4.2 Results	103
4.2.1 Prevalence of <i>H. influenzae</i>, <i>S. pneumoniae</i> and <i>M. catarrhalis</i> in Aboriginal and non-Aboriginal children	104
4.2.2 Nasopharyngeal colonization and the salivary IgA response	110
4.2.3 Nasopharyngeal colonization and specific salivary IgA responses	114
4.2.4 Carriage load and specific salivary IgA responses	122
4.3 Discussion	128

Chapter 5. Environmental Influences on the salivary IgA development

5.1 Introduction	135
5.2 Results	136
5.2.1 Season	136
5.2.2 Crowding	144
5.2.3 Having an older sibling	151
5.2.4 Having a sibling in school	156
5.2.5 Having a sibling in daycare	161
5.2.6 Exposure to Indoor Smoking	166
5.2.7 Maternal smoking	173
5.2.7.1 Smoking vs. non-smoking	173
5.2.7.2 Maternal smoking habit (indoor vs. outdoors)	179
5.2.8 Breast milk IgA	183
5.3 Discussion	192

Chapter 6. Discussion and Conclusion

6.1 Discussion and conclusion	201
References	212
Appendices	236

List of Tables

Chapter 2

Table 2.1. Antigen coating concentrations for breast milk.	58
Table 2.2. Antigen coating concentrations for saliva.	58
Table 2.3. Breast milk quality control sample dilutions and absorbance values.	
Table 2.4. Saliva quality control sample dilutions and absorbance values.	59
Table 2.5. Intra-plate coefficient of variation for ELISA assays.	60
Table 2.6. Inter-plate coefficient of variation for ELISA assays.	60
Table 2.7. Summary of statistical analysis undertaken in chapter 3	62
Table 2.8. Summary of statistical analysis undertaken in chapter 4	63
Table 2.9. Summary of statistical analysis undertaken in chapter 5	64

Chapter 3

Table 3.1. The frequency table of the number of samples collected for each child.	68
Table 3.2. Percentages of saliva samples that had a detectable IgA in saliva for each age group and the significant values comparing the percentage of responders to each antigen according to age.	74
Table 3.3. Percentages of children with a detectable salivary IgA by indigenous status and gender: (a) for Aboriginal children and (b) for non-Aboriginal children.	88
Table 3.4. Distribution of saliva samples according to feeding group and age.	89
Table 3.5. The mean age, range and standard deviation at the first and second saliva collection time points. Saliva samples were placed into feeding groups based on feeding type of the child at the time of first and second saliva collection.	89
Table 3.6. The number of saliva samples in each feeding group by age and indigenous status.	93

Chapter 4

Table 4.1. Characteristics of children colonized and not colonized by <i>H. influenzae</i> : (a) for Aboriginal children, (b) for non-Aboriginal children.	105
Table 4.2. Characteristics of children colonized and not colonized by <i>S. pneumoniae</i> : (a) for Aboriginal children, (b) for non-Aboriginal children.	107
Table 4.3. Characteristics of children colonized and not colonized by <i>M. catarrhalis</i> ; (a) for Aboriginal children, (b) for non-Aboriginal children.	109

Table 4.4. A table of significant values comparing salivary IgA levels between <i>H. influenzae</i> colonized and non-colonized children for each age group.	111
Table 4.5. A table of significant values from comparing salivary IgA levels between <i>S. pneumoniae</i> colonized and non-colonized children for each age group.	112
Table 4.6. A table of significant values from comparing salivary total IgA levels between <i>M. catarrhalis</i> colonized and non-colonized children for each age group.	113
Table 4.7. Percentages of children with a positive antibody response for Aboriginal and non-Aboriginal children according to age and <i>H. influenzae</i> colonization status.	116
Table 4.8. A table of significant values comparing the percentage of responders to P6 and OMP26 antigens among <i>H. influenzae</i> colonized children between indigenous groups.	116
Table 4.9. Percentages of children with a positive antibody response for Aboriginal and non-Aboriginal children according to age and <i>S. pneumoniae</i> colonization status.	118
Table 4.10. A table of significant values comparing percentages of responders to pneumolysin and <i>S. pneumoniae</i> antigens among <i>S. pneumoniae</i> colonized children between indigenous groups.	118
Table 4.11. Percentages of children with a positive antibody response for Aboriginal and non-Aboriginal children according to age and <i>M. catarrhalis</i> colonization status.	121
Table 4.12. A table of significant values comparing the percentage of responders to OMPE and <i>M. catarrhalis</i> antigens among <i>M. catarrhalis</i> colonized children between indigenous groups.	121

Chapter 5

Table 5.1. The number of saliva samples in each age group based on the season of saliva collection.	138
Table 5.2. Distribution of saliva samples for each season according to indigenous status and age.	143
Table 5.3. Distribution of saliva samples for each season according to feeding group and age.	144
Table 5.4. Distribution of saliva samples according to crowding index and age. Both the number of samples as well as percentages are included.	145
Table 5.5. Distribution of saliva samples according to Aboriginality, age and crowding index.	149
Table 5.6. Distribution of saliva samples in each crowding group according to feeding type and age.	150

	
Table 5.7. Distribution of saliva samples (the number of samples and percentages) according to the presence of an older sibling and age.	151
Table 5.8. Distribution of saliva samples according to Aboriginality, the presence of an older sibling and age.	155
Table 5.9. Distribution of saliva samples according to feeding type, the presence of an older sibling and age.	156
Table 5.10. Distribution of saliva samples (both percentages and number) according to having a sibling in school, and age.	159
Table 5.11. Distribution of saliva samples according to having a sibling in school, Aboriginality and age.	160
Table 5.12. Distribution of saliva samples according to feeding type, having a sibling in school and age.	161
Table 5.13. Distribution of saliva samples according to sibling day care attendance and age.	162
Table 5.14. Distribution of saliva samples according to Aboriginality, sibling attendance at day care and age.	165
Table 5.15. Distribution of saliva samples according to feeding type, sibling day care attendance and age.	166
Table 5.16. Distribution of saliva samples according to indoor smoking exposure and age.	167
Table 5.17. Distribution of saliva samples according to Aboriginality, indoor smoke exposure and age.	171
Table 5.18. Percentage of responders to OMP26 for Aboriginal and non-Aboriginal children.	171
Table 5.19. Distribution of saliva samples according to feeding type, indoor smoke exposure and age.	172
Table 5.20. Sample distributions for maternal smoking status and age.	176
Table 5.21. Sample distributions according to Aboriginality, maternal smoking status and age.	177
Table 5.22. Percentage of responders to OMP26 and <i>S. pneumoniae</i> antigen according to maternal smoking status.	177
Table 5.23. Distribution of saliva samples in each group according to feeding type, maternal smoking status and age.	178

Table 5.24. The number of saliva samples in each group according to maternal indoor smoking and age.	182
Table 5.25. Distribution of saliva samples in each group according to Aboriginality, maternal indoor smoking status and age.	182
Table 5.26. Distribution of saliva samples in each group according to feeding type, maternal indoor smoking habit and age.	183
Table 5.27. A table of breast milk IgA levels according to indigenous status. P represent significant values from the Mann-Whitney U test.	187
Table 5.28. A table of breast milk IgA levels according to smoking habit. P represent significant values from the Mann-Whitney U test.	187
Table 5.29. A table of breast milk IgA levels according to crowding index. P represents significant values from the Mann-Whitney U test.	188
Table 5.30. A table of breast milk IgA levels according to parity. P represents significant values from the Mann-Whitney U test.	188
Table 5.31. A table of breast milk IgA levels according to employment status. P represents significant values from the Mann-Whitney U test.	189
 Chapter 6		
Table 6.1. A Summary of significant findings in chapter 3	204
Table 6.2. A summary of significant finding in chapter 4	205
Table 6.3. A summary of significant findings in chapter 5	206

List of Figures

Chapter 1

Figure 1.1. Lymphocyte homing and migration.	4
Figure 1.2. A model for secretory component (SC)-mediated epithelial transport of dimeric IgA.	6
Figure 1.3. Integration of mucosal immunity between mother and the newborn	15

Chapter 3

Figure 3.1 (a) to (g). Specific and salivary IgA levels ($\mu\text{g/ml}$) with age: (a) Salivary IgA, (b) anti-P6 IgA, (c) anti-OMP26 IgA, (d) anti-OMPE IgA, (e) anti- <i>M. catarrhalis</i> IgA, (f) anti-pneumolysin IgA and (g) anti- <i>S. pneumoniae</i> IgA.	70
Figure 3.2 (a) to (g). Salivary and specific IgA levels ($\mu\text{g/ml}$) in saliva according to age for positive responders. Graphs are (a) salivary IgA, (b) anti-P6 IgA, (c) anti-OMP26 IgA, (d) anti-OMPE IgA, (e) anti- <i>M. catarrhalis</i> IgA, (f) anti-pneumolysin IgA and (g) anti- <i>S. pneumoniae</i> IgA.	76
Figure 3.3. Salivary IgA antibody ($\mu\text{g/ml}$) levels according to age and Aboriginality.	80
Figure 3.4. <i>H. influenzae</i> specific salivary IgA levels ($\mu\text{g/ml}$) according to age and Aboriginality: (a) anti-P6 IgA and (b) anti-OMP26 IgA.	82
Figure 3.5. <i>M. catarrhalis</i> specific salivary IgA levels ($\mu\text{g/ml}$) according to age and Aboriginality: (a) anti-OMPE IgA and (b) anti- <i>M. catarrhalis</i> IgA.	84
Figure 3.6. <i>S. pneumoniae</i> specific salivary IgA levels ($\mu\text{g/ml}$) according to age and Aboriginality: (a) anti-pneumolysin IgA and (b) anti- <i>S. pneumoniae</i> IgA.	86
Figure 3.7 (a) to (g). Salivary IgA levels ($\mu\text{g/ml}$) by age and feeding type: (a) salivary IgA, (b) anti-P6 IgA, (c) anti-OMP26 IgA, (d) anti-OMPE IgA, (e) anti- <i>M. catarrhalis</i> IgA, (f) anti-pneumolysin IgA and (g) anti- <i>S. pneumoniae</i> IgA.	90

Chapter 4

Figure 4.1. The percentage of Aboriginal and non-Aboriginal children colonized by <i>H. influenzae</i> for each age group.	105
Figure 4.2. The percentage of Aboriginal and non-Aboriginal children colonized by <i>S. pneumoniae</i> for each	107

age group.

Figure 4.3. The percentage of Aboriginal and non-Aboriginal children colonized by <i>M. catarrhalis</i> for each age group.	109
Figure 4.4. Salivary IgA levels ($\mu\text{g/ml}$) according to age for <i>H. influenzae</i> colonized and non-colonized children.	111
Figure 4.5. Salivary IgA levels ($\mu\text{g/ml}$) according to age for <i>S. pneumoniae</i> colonized and non-colonized children.	112
Figure 4.6. Salivary total IgA levels ($\mu\text{g/ml}$) according age for <i>M. catarrhalis</i> colonized and non-colonized children.	113
Figure 4.7. P6 and OMP26 specific IgA responses ($\mu\text{g/ml}$) in saliva of Aboriginal and non-Aboriginal children with and without the presence of <i>H. influenzae</i> .	115
Figure 4.8. Specific IgA levels ($\mu\text{g/ml}$) in saliva in Aboriginal and non-Aboriginal children with and without the presence of <i>S. pneumoniae</i> .	117
Figure 4.9. Specific IgA levels ($\mu\text{g/ml}$) in saliva in Aboriginal and non-Aboriginal children with and without the presence of <i>M. catarrhalis</i> .	120
Figure 4.10. <i>H. influenzae</i> specific salivary IgA levels ($\mu\text{g/ml}$) and carriage load according to indigenous status and age.	123
Figure 4.11. <i>S. pneumoniae</i> specific salivary IgA levels ($\mu\text{g/ml}$) and carriage load according to indigenous status and age.	125
Figure 4.12. <i>M. catarrhalis</i> specific salivary IgA levels ($\mu\text{g/ml}$) and carriage load according to indigenous status and age.	127

Chapter 5

Figure 5.1. Median salivary IgA levels for samples collected in each month independent of age and mean minimum monthly temperatures in the Kalgoorlie-Boulder area.	137
Figure 5.2. Salivary IgA levels ($\mu\text{g/ml}$) according to age and season (a) salivary IgA (b) anti-P6 IgA (c) anti-OMP26 IgA.	139
Figure 5.3. Salivary IgA levels ($\mu\text{g/ml}$) according to age and season (a) anti-OMPE IgA (b) Anti- <i>M. catarrhalis</i> composite IgA (c) Anti-pneumolysin IgA (d) Anti- <i>S. pneumoniae</i> IgA.	140
Figure 5.4 Salivary IgA levels ($\mu\text{g/ml}$) according to age and crowding index: (a) salivary IgA, (b) anti-P6 IgA, and (c) anti-OMP26 IgA.	146

Figure 5.5 Salivary IgA levels ($\mu\text{g/ml}$) according to age and crowding index (a) anti-OMPE IgA, (b) anti- <i>M. catarrhalis</i> IgA, (c) anti-pneumolysin IgA, (d) anti- <i>S. pneumoniae</i> IgA.	147
Figure 5.6. Salivary IgA levels ($\mu\text{g/ml}$) according to age and having an older sibling: (a) salivary IgA, (b) anti-P6 IgA, and (c) anti-OMP26 IgA.	152
Figure 5.7. Salivary IgA levels ($\mu\text{g/ml}$) by age and having an older sibling: (a) anti-OMPE IgA, (b) anti- <i>M. catarrhalis</i> IgA, and (c) anti-pneumolysin IgA (d) anti- <i>S. pneumoniae</i> IgA.	153
Figure 5.8. Salivary IgA levels ($\mu\text{g/ml}$) according to having a sibling in school and age: (a) salivary IgA, (b) anti-P6 IgA, and (c) anti-OMP26 IgA.	157
Figure 5.9. Salivary IgA levels ($\mu\text{g/ml}$) according to having a sibling in school and age: (a) anti-OMPE IgA, (b) anti- <i>M. catarrhalis</i> IgA, (c) anti-pneumolysin IgA, and (d) anti- <i>S. pneumoniae</i> IgA.	158
Figure 5.10. Salivary IgA levels ($\mu\text{g/ml}$) according to sibling attendance at day care, and age: (a) salivary IgA, (b) anti-P6 IgA, and (c) anti-OMP26 IgA.	163
Figure 5.11. Salivary IgA levels ($\mu\text{g/ml}$) according to sibling attendance at day care, and age: (a) anti-OMPE IgA (b) anti- <i>M. catarrhalis</i> IgA (c) anti-pneumolysin IgA (d) anti- <i>S. pneumoniae</i> IgA.	164
Figure 5.12. Salivary IgA levels ($\mu\text{g/ml}$) according to indoor smoke exposure, and age: (a) salivary IgA, (b) anti-P6 IgA and (c) anti-OMP26 IgA.	168
Figure 5.13. Salivary IgA levels ($\mu\text{g/ml}$) according to indoor smoke exposure, and age: (a) anti-OMPE IgA, (b) anti- <i>M. catarrhalis</i> IgA, (c) anti-pneumolysin IgA and (d) <i>S. pneumoniae</i> IgA.	169
Figure 5.14. Salivary IgA levels ($\mu\text{g/ml}$) according to maternal smoking status and age: (a) salivary IgA, (b) anti-P6 IgA, and (c) anti-OMP26 IgA.	174
Figure 5.15. Salivary IgA levels ($\mu\text{g/ml}$) according to maternal smoking status and age: (a) anti-OMPE IgA, (b) anti- <i>M. catarrhalis</i> IgA, (c) anti-pneumolysin IgA and (d) anti- <i>S. pneumoniae</i> IgA.	175
Figure 5.16. Salivary IgA levels ($\mu\text{g/ml}$) with respect to maternal indoor smoking exposure: (a) salivary IgA, (b) anti-P6 IgA, and (c) anti-OMP26 IgA.	180
Figure 5.17. Salivary IgA levels ($\mu\text{g/ml}$) with respect to maternal indoor smoking exposure: (a) anti-OMPE IgA, (b) anti- <i>M. catarrhalis</i> IgA, (c) anti-pneumolysin IgA, and (d)	181

anti-*S. pneumoniae* IgA.

Figure 5.18 Median breast milk IgA levels ($\mu\text{g/ml}$) with regard to (a) Aboriginality and (b) smoking status.	185
Figure 5.19 Median breast milk IgA levels ($\mu\text{g/ml}$) with regard to (a) crowding index, (b) employment, and (c) parity.	186
Figure 5.20. (a to g). General salivary IgA and specific IgA scatter plots for matching breast milk and saliva samples: (a) salivary IgA, (b) anti-P6 IgA, (c) anti-OMP26 IgA, (d) anti-OMPE IgA, (e) anti- <i>M. catarrhalis</i> IgA, (f) anti-pneumolysin IgA and (g) anti- <i>S. pneumoniae</i> IgA.	190

List of Abbreviations

AOM	Acute otitis media
BALT	Bronchus-associated lymphoid tissue
BSA	Bovine serum albumin
ELISA	Enzyme linked immunosorbent assay
g	Gravitational force
GALT	Gut-associated lymphoid tissue
Hi	<i>H. influenzae</i>
Hib	<i>Haemophilus influenzae</i> type b
HLA	Human leukocyte antigen
IgA	Immunoglobulin A
IgM	Immunoglobulin M
IgG	Immunoglobulin G
IL	Interleukin
Kda	Kilodalton
LB	Luria-Bertani
LMW	Low molecular weight
NTHi	Non-typeable <i>Haemophilus influenzae</i>
OD	Optical density
OM	Otitis Media
OME	Otitis media with effusion
OMP	Outer membrane protein
PAGE	Polyacrylamide gel electrophoresis
PBS	Phosphate buffered saline
PIgR	Polyimmunoglobulin receptor
Ply	Pneumolysin

PnPs	Pneumococcal polysaccharide
PsaA	Pneumococcal surface adhesin A
PspA	Pneumococcal surface protein A
QC	Quality control
rAOM	Recurrent acute otitis media
RER	Rough endoplasmic reticulum
SC	Secretory component
SDS	Sodium dodecyl sulphate
SIgA	Secretory IgA
TGF- β	Transforming growth factor-beta
TMB	Tetramethylbenzidine
TNF- α	Tumor necrosis factor-alpha
TRIS	Tris (hydroxymethyl)-aminomethane
UspA	Ubiquitous surface protein A
% CV	Coefficient of variation